series-a
Stage
1
Investors
About
Poplar Therapeutics is developing a new class of anti-IgE therapies to treat food allergies and other atopic conditions by targeting immunoglobulin E (IgE).
Explore Poplar Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.